We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
General Electric (GE), Boston Scientific Bond Over Heartcare
Read MoreHide Full Article
Wipro GE Healthcare, the joint venture of General Electric Company (GE - Free Report) , USA and Wipro Enterprises Limited, India, recently collaborated with Boston Scientific Corporation (BSX - Free Report) . The deal will involve both companies in providing innovative interventional cardiac care solutions in India.
Headquartered in Natick, MA, Boston Scientific manufactures medical devices and products used in various interventional medical specialties worldwide. BSX adopted both organic and inorganic routes for success.
In March 2022, Boston Scientific partnered with Ainnova Tech to develop a digital health platform called HealthConnnect. The platform is designed to prevent diseases through early detection using artificial intelligence.
Image Source: Zacks Investment Research
Coming back to General Electric, its share price increased 1.8% on the last trading day, eventually closing the session at $76.10. In the past six months, its share price has decreased 21% compared with the industry’s decline of 3.9%.
Inside the Headline
This first-of-its-kind partnership will enable cardiac patients to get easier access to heart care treatment. GE Healthcare’s robust medical imaging systems, such as cardiac catheterization lab and other related software coupled with Boston Scientific’s state-of-the-art medical devices and other capabilities, will aid in treating patients and keeping track of the cardiac patient-care pathway.
Per the deal, both companies will also focus on training and educating the healthcare professionals on the advanced technologies available, thus enabling them to take more informed decisions on the diagnosis and treatment of cardiac diseases. This, in turn, will lead to better patient outcomes. GE had also entered into a similar partnership with Boston Scientific earlier this year to provide cardiology solutions besides training and educating their clients.
Zacks Rank & Stocks to Consider
GE currently carries a Zacks Rank #3 (Hold). Some better-ranked companies are discussed below.
In the past 60 days, Carlisle’s earnings estimates have increased 14.6% for 2022. The stock has rallied 28% in the past six months.
Griffon Corporation (GFF - Free Report) has a Zacks Rank #2 (Buy). GFF delivered a trailing four-quarter earnings surprise of 104.6%, on average.
In the past 60 days, Griffon’s earnings estimates have increased 3% for fiscal 2022 (ending September 2022). The stock has soared 46.3% in the past six months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
General Electric (GE), Boston Scientific Bond Over Heartcare
Wipro GE Healthcare, the joint venture of General Electric Company (GE - Free Report) , USA and Wipro Enterprises Limited, India, recently collaborated with Boston Scientific Corporation (BSX - Free Report) . The deal will involve both companies in providing innovative interventional cardiac care solutions in India.
Headquartered in Natick, MA, Boston Scientific manufactures medical devices and products used in various interventional medical specialties worldwide. BSX adopted both organic and inorganic routes for success.
In March 2022, Boston Scientific partnered with Ainnova Tech to develop a digital health platform called HealthConnnect. The platform is designed to prevent diseases through early detection using artificial intelligence.
Image Source: Zacks Investment Research
Coming back to General Electric, its share price increased 1.8% on the last trading day, eventually closing the session at $76.10. In the past six months, its share price has decreased 21% compared with the industry’s decline of 3.9%.
Inside the Headline
This first-of-its-kind partnership will enable cardiac patients to get easier access to heart care treatment. GE Healthcare’s robust medical imaging systems, such as cardiac catheterization lab and other related software coupled with Boston Scientific’s state-of-the-art medical devices and other capabilities, will aid in treating patients and keeping track of the cardiac patient-care pathway.
Per the deal, both companies will also focus on training and educating the healthcare professionals on the advanced technologies available, thus enabling them to take more informed decisions on the diagnosis and treatment of cardiac diseases. This, in turn, will lead to better patient outcomes. GE had also entered into a similar partnership with Boston Scientific earlier this year to provide cardiology solutions besides training and educating their clients.
Zacks Rank & Stocks to Consider
GE currently carries a Zacks Rank #3 (Hold). Some better-ranked companies are discussed below.
Carlisle Companies (CSL - Free Report) sports a Zacks Rank #1 (Strong Buy), currently. CSL pulled off a trailing four-quarter earnings surprise of 28%, on average. You can see the complete list of today’s Zacks #1 Rank stocks.
In the past 60 days, Carlisle’s earnings estimates have increased 14.6% for 2022. The stock has rallied 28% in the past six months.
Griffon Corporation (GFF - Free Report) has a Zacks Rank #2 (Buy). GFF delivered a trailing four-quarter earnings surprise of 104.6%, on average.
In the past 60 days, Griffon’s earnings estimates have increased 3% for fiscal 2022 (ending September 2022). The stock has soared 46.3% in the past six months.